Cover Image
市場調查報告書

注意力不足過動症(ADHD):開發平台分析

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232850
出版日期 內容資訊 英文 167 Pages
訂單完成後即時交付
價格
Back to Top
注意力不足過動症(ADHD):開發平台分析 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 167 Pages
簡介

所謂注意缺陷過動症(ADHD),是指集中力維持困難,有多動性、衝動的行動頻發等特徵的精神衛生狀態。主要的症狀,是難進行組織性行動,難以遵守時間,難維持一個工作、活動的集中力。主要的治療藥有興奮藥等。

本報告提供全球各國的注意力不足過動症(ADHD)治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

注意力不足過動症(ADHD)概要

治療藥的開發

  • ADHD開發中產品:概要
  • ADHD開發中產品:比較分析

各企業開發中的ADHD治療藥

大學/研究機關研究中的ADHD治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段的產品

ADHD治療藥:開發中的產品一覽(各企業)

ADHD治療藥:研究中的產品一覽(各大學/研究機關)

ADHD開發治療藥的企業

  • Alcobra Ltd
  • Amarantus Bioscience Holdings, Inc.
  • APeT Holding BV
  • Arbor Pharmaceuticals, LLC.
  • BCWorld Pharm Co. Ltd.
  • Collegium Pharmaceutical, Inc.
  • Curemark, LLC
  • Domain Therapeutics SA
  • DURECT Corporation
  • Ensysce Biosciences Inc.
  • H. Lundbeck A/S
  • Heptares Therapeutics Limited
  • Highland Therapeutics, Inc.
  • 久光製藥
  • Integrative Research Laboratories Sweden AB
  • Intra-Cellular Therapies, Inc.
  • INVENT Pharmaceuticals, Inc.
  • KemPharm, Inc.
  • Luc Therapeutics, Inc.
  • Medgenics Inc.
  • Merck & Co., Inc.
  • Neos Therapeutics, Inc.
  • NeuroDerm Ltd.
  • Neurovance, Inc.
  • NLS Pharma Group
  • P2D Bioscience
  • Polleo Pharma Limited
  • Reviva Pharmaceuticals Inc.
  • Shire Plc
  • Sunovion Pharmaceuticals Inc.
  • Supernus Pharmaceuticals, Inc.
  • Taisho Pharmaceutical Holdings Co., Ltd.
  • TRImaran Pharma, Inc.
  • Vernalis Plc

ADHD:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 各標的
  • 各作用機制
  • 各投藥法
  • 各分子類型
  • 各治療分類

藥物簡介

  • (nicotine + opipramol hydrochloride)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • AR-08
  • BCWPE-003
  • BLI-1008
  • BNC-375
  • CB-8411
  • centanafadine IR
  • centanafadine SR
  • CM-4612
  • CTX-1301
  • CTX-1302
  • dasotraline hydrochloride
  • dextroamphetamine
  • dextroamphetamine MR
  • eltoprazine
  • etiguanfacine
  • guanfacine hydrochloride ER
  • 組織胺二鹽酸鹽
  • HTL-1071
  • INV-170
  • IRL-752
  • ITI-214
  • KP-415 CR
  • lisdexamfetamine dimesylate
  • mazindol
  • Metadoxine ER
  • methylphenidate hydrochloride ER
  • methylphenidate hydrochloride MR
  • methylphenidate hydrochloride SR
  • methylphenidate hydrochloride XR
  • MGS-0028
  • molindone hydrochloride ER
  • NFC-1
  • niacinamide CR
  • NLS-3
  • NLS-4
  • NT-0201
  • P-001
  • PBF-509
  • PD-2005
  • PD-3044
  • PFR-08001
  • PFR-8026
  • RP-5063
  • SHP-465
  • ADHD用多巴胺、腎上腺髓質荷爾蒙、血清素運輸體阻斷劑
  • ADHD用小分子
  • ADHD、思覺失調症用GPR88促效劑
  • ADHD用NMDA2D促效劑
  • ADHD用多巴胺運輸體抑制劑
  • 中樞神經、代謝障礙用多巴胺運輸體抑制劑
  • 中樞神經系統障礙用多巴胺、血清素、腎上腺髓質荷爾蒙運輸體抑制劑
  • ADHD用碳酸氫鈉替換體抑制劑
  • ADHD用膽鹼運輸體修飾用小分子
  • V-81444
  • 中樞神經系統障礙用疫苗
  • viloxazine hydrochloride ER
  • vortioxetine hydrobromide
  • VU-0238429

ADHD治療藥:開發中產品的最新趨勢

ADHD治療藥:開發暫停的產品

ADHD治療藥:開發中止的產品

ADHD相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9064IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder - Pipeline Review, H1 2017, provides an overview of the Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline landscape.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 6, 11, 8, 15, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.

Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Attention Deficit Hyperactivity Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Attention Deficit Hyperactivity Disorder (ADHD) - Overview
  • Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development
    • Aevi Genomic Medicine Inc
    • Alcobra Ltd
    • Amarantus Bioscience Holdings Inc
    • APeT Holding BV
    • Arbor Pharmaceuticals LLC
    • BCWorld Pharm Co Ltd
    • BioHealthonomics Inc
    • BioLite Inc
    • Cingulate Therapeutics LLC
    • Collegium Pharmaceutical Inc
    • Curemark LLC
    • DURECT Corp
    • Eli Lilly and Company
    • Ensysce Biosciences Inc
    • H. Lundbeck A/S
    • Heptares Therapeutics Ltd
    • Highland Therapeutics Inc
    • Integrative Research Laboratories Sweden AB
    • INVENT Pharmaceuticals Inc
    • KemPharm Inc
    • Luc Therapeutics Inc
    • Merck & Co Inc
    • Neos Therapeutics Inc
    • NeuroDerm Ltd
    • Neurovance Inc
    • NLS Pharma Group
    • Noven Pharmaceuticals Inc
    • P2D Bioscience
    • Reviva Pharmaceuticals Inc
    • Shire Plc
    • SK Biopharmaceuticals Co Ltd
    • Sunovion Pharmaceuticals Inc
    • Supernus Pharmaceuticals Inc
    • Taisho Pharmaceutical Co Ltd
    • TRImaran Pharma Inc
  • Attention Deficit Hyperactivity Disorder (ADHD) - Drug Profiles
    • (nicotine + opipramol hydrochloride) - Drug Profile
    • 4-P003 - Drug Profile
    • AR-08 - Drug Profile
    • BCWPE-003 - Drug Profile
    • BLI-1008 - Drug Profile
    • BNC-375 - Drug Profile
    • CB-8411 - Drug Profile
    • centanafadine SR - Drug Profile
    • CM-4612 - Drug Profile
    • CTX-1301 - Drug Profile
    • CTX-1302 - Drug Profile
    • dasotraline hydrochloride - Drug Profile
    • dextroamphetamine - Drug Profile
    • dextroamphetamine IR - Drug Profile
    • dextroamphetamine MR - Drug Profile
    • edivoxetine hydrochloride - Drug Profile
    • eltoprazine - Drug Profile
    • fasoracetam - Drug Profile
    • guanfacine hydrochloride ER - Drug Profile
    • histamine dihydrochloride - Drug Profile
    • HTL-1071 - Drug Profile
    • INV-107 - Drug Profile
    • IRL-752 - Drug Profile
    • KP-415 CR - Drug Profile
    • levofacetoperane - Drug Profile
    • lisdexamfetamine dimesylate - Drug Profile
    • mazindol - Drug Profile
    • methylphenidate hydrochloride ER - Drug Profile
    • methylphenidate hydrochloride MR - Drug Profile
    • methylphenidate hydrochloride SR - Drug Profile
    • methylphenidate hydrochloride XR - Drug Profile
    • modafinil - Drug Profile
    • molindone hydrochloride ER - Drug Profile
    • niacinamide CR - Drug Profile
    • NLS-4 - Drug Profile
    • NLS-8 - Drug Profile
    • NT-0201 - Drug Profile
    • P-001 - Drug Profile
    • PBF-509 - Drug Profile
    • PD-2005 - Drug Profile
    • PD-3044 - Drug Profile
    • PFR-08001 - Drug Profile
    • PFR-8026 - Drug Profile
    • RP-5063 - Drug Profile
    • SHP-465 - Drug Profile
    • SKL-ADHD - Drug Profile
    • Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile
    • Small Molecules to Activate High Affinity Choline Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile
    • Small Molecules to Agonize NMDA2D for Attention Deficit Hyperactivity Disorder - Drug Profile
    • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
    • Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
    • Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile
    • Synthetic Peptide to Antagonize D2 for ADHD - Drug Profile
    • TS-141 - Drug Profile
    • Vaccine for CNS Disorders - Drug Profile
    • viloxazine hydrochloride ER - Drug Profile
    • vortioxetine hydrobromide - Drug Profile
    • VU-0238429 - Drug Profile
  • Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects
  • Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products
  • Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Aevi Genomic Medicine Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals LLC, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioHealthonomics Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioLite Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Ensysce Biosciences Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Integrative Research Laboratories Sweden AB, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by INVENT Pharmaceuticals Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neurovance Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NLS Pharma Group, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Co Ltd, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by TRImaran Pharma Inc, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top